Anti-Human CD19 Reference Antibody (Taplitumomab, RUO) (HV426036)

Name: Anti-Human CD19 Reference Antibody (Taplitumomab, RUO)
Brand: abinScience
SKU: HV426036
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV426036
Descripción	Taplitumomab (HV426036) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Mouse
Clonalidad	Monoclonal
Isotipo	IgG2a-kappa
Sistema de expresión	Mammalian cells
Objetivo	CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P15391
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	235428-87-2
Fondo	B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi). 1. Vanshylla, K. et al. (2018) Scientific reports 8, 4244. PMID: 29523808 2. Carter, RH. et al. (1992) Science (New York, N.Y.) 256, 105-7. PMID: 1373518 3. van Zelm, MC. et al. (2006) The New England journal of medicine 354, 1901-12. PMID: 16672701 4. de Rie, MA. et al. (1989) Cellular immunology 118, 368-81. PMID: 2463100 5. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743 6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126 7. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Mouse IgG2a (Fc Silence) Recombinant Isotype Control (MOPC 173) (MF533023)